TR201907379T4 - Yeni anti-insan PAI-1 antikoru. - Google Patents
Yeni anti-insan PAI-1 antikoru. Download PDFInfo
- Publication number
- TR201907379T4 TR201907379T4 TR2019/07379T TR201907379T TR201907379T4 TR 201907379 T4 TR201907379 T4 TR 201907379T4 TR 2019/07379 T TR2019/07379 T TR 2019/07379T TR 201907379 T TR201907379 T TR 201907379T TR 201907379 T4 TR201907379 T4 TR 201907379T4
- Authority
- TR
- Turkey
- Prior art keywords
- human pai
- antibody
- pai
- seq
- new anti
- Prior art date
Links
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 title abstract 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 title abstract 3
- 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 102000043283 human SERPINE1 Human genes 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Aktif insan PAI-1'e bağlanmak ve aktif insan PAI-1'in aracılık ettiği etkileri inhibe etmek suretiyle pulmoner fibrozu önlemek veya tedavi etmek için bir anti-insan PAI-1 antikoru sağlamak. [Çözüm için Araçlar] Mevcut buluşun sahipleri anti-PAI-1 antikorlarını incelemiş ve sonuç olarak SEQ ID NO:2'deki 1 ila 118 numaralı amino asitlerden oluşan amino asit dizisinden meydana gelen bir ağır zincir değişken bölgesini ve SEQ ID NO:4'teki 1 ila 108 numaralı amino asitlerden oluşan amino asit dizisinden meydana gelen bir hafif zincir değişken bölgesini içeren bir anti-insan PAI-1 antikoru sağlamıştır.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014031319 | 2014-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201907379T4 true TR201907379T4 (tr) | 2019-06-21 |
Family
ID=53878402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/07379T TR201907379T4 (tr) | 2014-02-21 | 2015-02-20 | Yeni anti-insan PAI-1 antikoru. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9803024B2 (tr) |
| EP (1) | EP3109320B1 (tr) |
| JP (1) | JP6512213B2 (tr) |
| KR (1) | KR20160124840A (tr) |
| CN (1) | CN106029884B (tr) |
| BR (1) | BR112016019332A2 (tr) |
| CA (1) | CA2939897A1 (tr) |
| ES (1) | ES2726915T3 (tr) |
| MX (1) | MX2016010852A (tr) |
| PL (1) | PL3109320T3 (tr) |
| PT (1) | PT3109320T (tr) |
| RU (1) | RU2016137486A (tr) |
| TR (1) | TR201907379T4 (tr) |
| WO (1) | WO2015125904A1 (tr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3046671C (en) * | 2016-12-15 | 2023-08-08 | Talengen International Limited | Method for preventing and treating pulmonary fibrosis |
| CA3047170A1 (en) * | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for preventing and treating drug-induced renal injury |
| US11938172B2 (en) | 2017-06-19 | 2024-03-26 | Talengen International Limited | Method for regulating and controlling GLP-1/GLP-1R and drug |
| EP4039276A4 (en) | 2019-09-30 | 2023-11-15 | Renascience Inc. | INHIBITOR AGAINST THE EXPRESSION OF AN IMMUNE CHECKPOINT MOLECULE |
| CN111072780B (zh) * | 2020-03-24 | 2020-06-23 | 深圳汉盛汇融再生医学科技有限公司 | 白血病干细胞抑制剂及其在治疗慢性粒细胞白血病中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3742997A1 (de) * | 1987-12-18 | 1989-06-29 | Behringwerke Ag | Peptide, verfahren zu ihrer herstellung, ihre verwendung zur gewinnung von antikoerpern sowie deren verwendung zur blockierung der pai-1-aktivitaet menschlichen blutes |
| AU2002216847A1 (en) * | 2000-10-26 | 2002-05-06 | K.U. Leuven Research And Development | Epitopes of pai-1 |
| AU2003301809A1 (en) * | 2002-05-13 | 2004-06-07 | Children's Hospital Los Angeles | Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions |
| EP2198055A4 (en) * | 2007-09-07 | 2012-04-18 | Cisthera Inc | HUMANIZED PAI-1 ANTIBODIES |
| CN101654405A (zh) * | 2008-08-19 | 2010-02-24 | 信谊药厂 | 抗凝化合物、组合物及其用途 |
| US20100254979A1 (en) | 2009-03-06 | 2010-10-07 | Cisthera, Incorporated | Humanized PAI-1 Antibodies and Uses Thereof |
| WO2011139973A2 (en) * | 2010-05-03 | 2011-11-10 | Abbott Laboratories | Methods of inhibiting fibrosis using anti-pai-1 antibodies |
-
2015
- 2015-02-20 EP EP15751458.9A patent/EP3109320B1/en active Active
- 2015-02-20 KR KR1020167025778A patent/KR20160124840A/ko unknown
- 2015-02-20 WO PCT/JP2015/054704 patent/WO2015125904A1/ja active Application Filing
- 2015-02-20 CN CN201580009780.9A patent/CN106029884B/zh active Active
- 2015-02-20 TR TR2019/07379T patent/TR201907379T4/tr unknown
- 2015-02-20 MX MX2016010852A patent/MX2016010852A/es unknown
- 2015-02-20 ES ES15751458T patent/ES2726915T3/es active Active
- 2015-02-20 RU RU2016137486A patent/RU2016137486A/ru not_active Application Discontinuation
- 2015-02-20 JP JP2016504181A patent/JP6512213B2/ja active Active
- 2015-02-20 PL PL15751458T patent/PL3109320T3/pl unknown
- 2015-02-20 US US15/120,257 patent/US9803024B2/en active Active
- 2015-02-20 CA CA2939897A patent/CA2939897A1/en not_active Abandoned
- 2015-02-20 BR BR112016019332A patent/BR112016019332A2/pt not_active IP Right Cessation
- 2015-02-20 PT PT15751458T patent/PT3109320T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016010852A (es) | 2016-10-26 |
| PT3109320T (pt) | 2019-06-06 |
| CN106029884A (zh) | 2016-10-12 |
| PL3109320T3 (pl) | 2019-08-30 |
| WO2015125904A1 (ja) | 2015-08-27 |
| ES2726915T3 (es) | 2019-10-10 |
| US9803024B2 (en) | 2017-10-31 |
| US20160369008A1 (en) | 2016-12-22 |
| KR20160124840A (ko) | 2016-10-28 |
| EP3109320A4 (en) | 2017-09-20 |
| CN106029884B (zh) | 2019-06-25 |
| JP6512213B2 (ja) | 2019-05-15 |
| EP3109320B1 (en) | 2019-03-27 |
| JPWO2015125904A1 (ja) | 2017-03-30 |
| CA2939897A1 (en) | 2015-08-27 |
| RU2016137486A (ru) | 2018-03-22 |
| EP3109320A1 (en) | 2016-12-28 |
| RU2016137486A3 (tr) | 2018-07-27 |
| BR112016019332A2 (pt) | 2017-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123163T1 (el) | Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| EA201892151A1 (ru) | Способ синтеза 2-гидрокси-6-((2-(1-изопропил-1h-пиразол-5-ил)пиридин-3-ил)метокси)бензальдегида | |
| CY1117655T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
| MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| EA201890315A1 (ru) | Молекулы антител, связывающие cd22 | |
| EA201491644A1 (ru) | Фармацевтические композиции | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| CY1116728T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
| EA201591908A1 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы | |
| EA201692502A1 (ru) | Лечение миелом | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| EA201500802A1 (ru) | Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы | |
| EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
| MX2018009498A (es) | Anticuerpos anti-tnf, composiciones, métodos y uso para el tratamiento o la prevención de la diabetes tipo 1. | |
| TR201907379T4 (tr) | Yeni anti-insan PAI-1 antikoru. | |
| EA201490717A1 (ru) | АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| MX2015006859A (es) | Anticuerpos anti-vegf y sus usos. | |
| PE20140190A1 (es) | Moduladores de proteinas notum y metodos de uso | |
| EA201590247A1 (ru) | Антитела к siglec-15 | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| EA201491832A1 (ru) | Способ обработки волос | |
| EA201692525A1 (ru) | Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов |